Novel Clostridium difficile Anti-Toxin TcdA and TcdB Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge ModelReportar como inadecuado




Novel Clostridium difficile Anti-Toxin TcdA and TcdB Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Clostridium difficile C. difficile infection CDI is the main cause of nosocomial antibiotic-associated colitis and increased incidence of community-associated diarrhea in industrialized countries. At present, the primary treatment of CDI is antibiotic administration, which is effective but often associated with recurrence, especially in the elderly. Pathogenic strains produce enterotoxin, toxin A TcdA, and cytotoxin, toxin B TcdB, which are necessary for C. difficile induced diarrhea and gut pathological changes. Administration of anti-toxin antibodies provides an alternative approach to treat CDI, and has shown promising results in preclinical and clinical studies. In the current study, several humanized anti-TcdA and anti-TcdB monoclonal antibodies were generated and their protective potency was characterized in a hamster infection model. The humanized anti-TcdA CANmAbA4 and anti-TcdB CANmAbB4 and CANmAbB1 antibodies showed broad spectrum in vitro neutralization of toxins from clinical strains and neutralization in a mouse toxin challenge model. Moreover, co-administration of humanized antibodies CANmAbA4 and CANmAbB4 cocktail provided a high level of protection in a dose dependent manner 85% versus 57% survival at day 22 for 50 mg-kg and 20 mg-kg doses, respectively in a hamster gastrointestinal infection GI model. This study describes the protective effects conferred by novel neutralizing anti-toxin monoclonal antibodies against C. difficile toxins and their potential as therapeutic agents in treating CDI.



Autor: Hongyu Qiu, Robyn Cassan, Darrell Johnstone, Xiaobing Han, Antony George Joyee, Monica McQuoid, Andrea Masi, John Merluza, Bryce

Fuente: http://plos.srce.hr/



DESCARGAR PDF




Documentos relacionados